PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
17300811-0	2007	Biphasic regulation of levofloxacin on lipopolysaccharide-induced IL-1beta production.	Levofloxacin	23-35	interleukin 1 beta	Mus musculus	66-74	
31319868-9	2019	The effect of CPFX and LVFX on LPS-induced release of IL-1beta and TNF-alpha and NF-kappaB activation was investigated in primary microglia by ELISA and fluorescence staining.	Levofloxacin	23-27	interleukin 1 beta	Mus musculus	54-62	
19554401-11	2009	Levofloxacin (100 mug/ml) inhibited IL-1beta production (65.0% of control), but not TNF-alpha production.	Levofloxacin	0-12	interleukin 1 beta	Mus musculus	36-44	
17300811-3	2007	In this study, we investigated the effect of levofloxacin on lipopolysaccharide (LPS)-induced production of interleukin-1beta (IL-1beta) in RAW264.7 cells.	Levofloxacin	45-57	interleukin 1 beta	Mus musculus	108-125	
17300811-3	2007	In this study, we investigated the effect of levofloxacin on lipopolysaccharide (LPS)-induced production of interleukin-1beta (IL-1beta) in RAW264.7 cells.	Levofloxacin	45-57	interleukin 1 beta	Mus musculus	127-135	
17300811-4	2007	We showed that LPS-stimulated release of pre-synthesized IL-1beta was promoted by levofloxacin, in part via the p38 mitogen-activated protein kinase (MAPK) pathway.	Levofloxacin	82-94	interleukin 1 beta	Mus musculus	57-65	
17300811-5	2007	On the other hand, newly synthesized IL-1beta production was inhibited by levofloxacin.	Levofloxacin	74-86	interleukin 1 beta	Mus musculus	37-45	
17300811-6	2007	This immunoregulatory function of levofloxacin in the later phase as well as promotion of pre-synthesized IL-1beta release by levofloxacin in the early phase might be advantageous in the host defense to microbial pathogens.	Levofloxacin	126-138	interleukin 1 beta	Mus musculus	106-114